Results from an international clinical trial, published June 15 in The Lancet, show that the selective targeted therapy, fruquintinib resulted in a statistically significant improvement in overall survival and progression-free survival.
New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that one’s biological age, which can be higher than his or her chronological age – a concept called accelerated aging – may predict who’s at risk for developing colon polyps, a known risk factor for colorectal cancer.
